# Add-on to Micamlo BP Trial

Study · id `cardio:ct-nct01975246` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01975246](<https://clinicaltrials.gov/study/NCT01975246>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01975246

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 309 participants.

## Technical summary

Registry record NCT01975246. Randomized; double masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2016-11-29.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 309 participants (enrolled count; ClinicalTrials.gov record NCT01975246, source copy `cardio:ctgov-nct01975246-2016-11-29`, retrieved 2026-10-26)
- Start date: 2013-11 (registry gives no type) (ClinicalTrials.gov record NCT01975246, source copy `cardio:ctgov-nct01975246-2016-11-29`, retrieved 2026-10-26)
- Primary completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01975246, source copy `cardio:ctgov-nct01975246-2016-11-29`, retrieved 2026-10-26)
- Completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01975246, source copy `cardio:ctgov-nct01975246-2016-11-29`, retrieved 2026-10-26)
- Results first posted: 2016-11-29 (ClinicalTrials.gov record NCT01975246, source copy `cardio:ctgov-nct01975246-2016-11-29`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01975246, source copy `cardio:ctgov-nct01975246-2016-11-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01975246-2016-11-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Add-on to Micamlo BP Trial
- Condition: Hypertension
- Intervention (Drug): Telmisartan + amlodipine
- Intervention (Drug): hydrochlorothiazide
- Intervention (Drug): Telmisartan + amlodipine
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Hydrochlorothiazide (`cardio:hydrochlorothiazide`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: d2080600b378e4839d8f6b98cac1ce4e99dc698ad825885901d7ef0d1c3eb9a3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
